Radiopharmaceuticals for Neurotransmitter Imaging.
- Author:
Seung Jun OH
1
Author Information
1. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. sjoh@amc.seoul.kr
- Publication Type:Review ; Clinical Trial
- Keywords:
PET;
SPECT;
radiopharmaceuticals;
dopamine transporter;
serotonin transporter
- MeSH:
Chemistry, Pharmaceutical;
Depression;
Dopamine;
Dopamine Plasma Membrane Transport Proteins;
Kinetics;
Neurotransmitter Agents*;
Parkinson Disease;
Radioactivity;
Radiopharmaceuticals*;
Serotonin;
Serotonin Plasma Membrane Transport Proteins;
Tomography, Emission-Computed, Single-Photon
- From:Nuclear Medicine and Molecular Imaging
2007;41(2):118-131
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Neurotransmitter imaging with radiopharmaceuticals plays major role for understanding of neurological and psychiatric disorders such as Parkinson's disease and depression. Radiopharmaceuticals for neurotransmitter imaging can be divided to dopamine transporter imaging radiopharmaceuticals and serotonin trnasporter imaging radiopharmaceuticals. Many kinds of new dopamine transporter imaging radiopharmcaeuticals has a tropane ring and they showed different biological properties according to the substituted functional group on tropane ring. After the first clinical trials with [123I]beta-CIT, alkyl chain substituent introduced to tropane ring amine to decrease time for imaging acquisition and to increase selectivity. From these results, [123I]PE2I, [18F]FE-CNT, [123I]FP-CIT and [18F]FP-CIT were developed and they showed high uptake on the dopamine transporter rich regions and fast peak uptake equilibrium time within 4 hours after injection. [11C]McN 5652 was developed for serotonin trnasporter imaging but this compound showed slow kinetics and high background radioactivity. To overcome these problems, new diarylsulfide backbone derivatives such as ADAM, ODAM, AFM, and DASB were developed. In these candidates, [11C]AFM and [11C]DASB showed high binding affinity to serotonin transporter and fast in vivo kinetics. This paper gives an overview of current status on dopamine and serotonin transporter imaging radiopharmaceuitcals and the development of new lead compounds as potential radiopharmaceuticals by medicinal chemistry.
